AbbVie stock climbs after Upadacitinib approval filings with FDA and EMA

Traders Union
All News
Financial News
AbbVie surges 3.35% on acquisition news

Highlights

AbbVie's $10.9 billion acquisition of Apogee Therapeutics strengthens its immunology pipeline with late-stage atopic dermatitis and asthma assets.
Recent regulatory milestones, including submissions for upadacitinib and MAVIRET’s European approval, expand AbbVie's therapeutic portfolio and support robust share demand.
ABBV shows strong bullish technical momentum, with price expected to consolidate between $235.87 and $249.67, though overbought conditions could signal near-term exhaustion.

Acquisition and regulatory wins drive optimism amid portfolio expansion

AbbVie has announced a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion in cash, a move that significantly expands its presence in the immunology sector and adds late-stage assets in atopic dermatitis and asthma, according to Forbes. This large-scale acquisition is indicative of AbbVie's commitment to diversifying its portfolio and driving long-term growth, directly fueling investor optimism. Additional regulatory initiatives, such as new FDA and EMA submissions for upadacitinib in non-segmental vitiligo as noted by Dermatologytimes, and the European Commission’s recent approval of MAVIRET for acute hepatitis C, reported by Indiamedtoday, further broaden the company’s therapeutic reach and support robust demand for its shares.

Bullish signals diverge from overbought indicators as caution rises

On the hourly chart, ABBV is positioned above the MA-20 at $234.19 and MA-50 at $226.4, while remaining above the MA-200 at $220.88 on the daily timeframe. The Ichimoku Kijun level at $228.92 marks immediate support. The Moving Average Convergence Divergence (MACD), Average Directional Index (ADX), and Awesome Oscillator are all in Buy territory, confirming ongoing bullish momentum. However, oscillators like the Relative Strength Index (RSI), Stochastic RSI, Commodity Channel Index (CCI), and Bull/Bear Power indicate overbought conditions, suggesting that although buyers currently dominate, the asset may be nearing a point of short-term exhaustion. This divergence between strong momentum signals and overbought oscillators warrants caution for new entrants.

Consolidation likely unless breakout or support breach shifts trend

Looking ahead over the next 2 to 3 trading days, ABBV is expected to trade within a volatility band of $235.87 to $249.67. The probability for a continued upward move stands at 75%, with a 25% likelihood of downside action. The baseline scenario calls for consolidation near current highs, while a decisive breakout above resistance may trigger further gains. If the price falls below the $228.92 support, a bearish scenario could emerge in the short term.

Viktoras Karapetjanc, Senior Financial Markets Analyst at Traders Union, sees the Apogee acquisition as a fundamental driver boosting AbbVie's position in immunology and pipeline strength. He notes that timely regulatory progress and expansion into new indications are fueling broad-based investor confidence. Technical signals remain bullish, but overbought momentum suggests careful monitoring for short-term pullbacks. "Strong fundamentals and positive sentiment continue to propel ABBV, but I would wait for minor dips to initiate or add to positions."

Previously it was reported that AbbVie’s bullish momentum remained intact, with analysts anticipating rangebound consolidation following a period of sustained gains and strategic expansion efforts. The current breakout-driven advance, underpinned by major acquisitions and accelerated regulatory activity, positions ABBV for renewed upside potential, making close monitoring of the $249.67 resistance level essential for traders assessing further momentum.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.